Waxman Seeks Phenylephrine NDAC Review; Cites Efficacy Concerns
This article was originally published in The Tan Sheet
Executive Summary
Rep. Henry Waxman (D-Calif.) is calling for an FDA advisory panel to reconsider the efficacy of the nasal decongestant phenylephrine and re-evaluate its status as a monograph ingredient
You may also be interested in...
Patient Symptoms Are Better Measure Of Decongestant’s Efficacy – FDA
The patient self-assessed nasal congestion symptom score, not nasal air resistance, is the preferred tool to evaluate the effectiveness of an oral nasal decongestant such as phenylephrine, according to a report by a division of FDA's Office of New Drugs
Patient Symptoms Are Better Measure Of Decongestant’s Efficacy – FDA
The patient self-assessed nasal congestion symptom score, not nasal air resistance, is the preferred tool to evaluate the effectiveness of an oral nasal decongestant such as phenylephrine, according to a report by a division of FDA's Office of New Drugs
Patient Symptoms Are Better Measure Of Decongestant’s Efficacy – FDA
The patient self-assessed nasal congestion symptom score, not nasal air resistance, is the preferred tool to evaluate the effectiveness of an oral nasal decongestant such as phenylephrine, according to a report by a division of FDA's Office of New Drugs